16 May 2026

68 days to PCAC. The Federal Register notice confirms the July 23–24 agenda and a July 9 advance-distribution deadline for public comments — comments after July 9 are still accepted through July 22 but not guaranteed to reach committee members ahead of the meeting. Zero new committee appointments. The Substack "Kennedy's FDA Just Brought BPC-157 Back From The Dead" is RFK-aligned narrative pressure but contains no procedural news. Historian: the reference class for FDA advisory reviews of bulk drug substances without USP monographs still anchors at ~20–30% Cat 1 rates; the Apr 15 Category-2 removal wave was conducted by FDA action, not by PCAC vote, so does not raise the reference-class base rate for Cat 1 conferral. Skeptic: falsifier unchanged — ≥3 RFK-aligned PCAC appointments before July 9. Zero progress on this falsifier in 16+ weeks. Bayesian: prior 0.55, posterior 0.55.

68 days. No USP monograph progress for any of the four named peptides. The Federal Register notice confirms 4-peptide agenda on July 23 plus additional peptides on July 24, reinforcing the crowded-agenda deferral risk. Bayesian: prior 0.58, posterior 0.58.

No new launch announcement from Hims & Hers today. CNBC's April 16 framing of peptides as "the next chapter" continues to dominate analyst discourse without confirmation of a specific molecule, price, or launch date. The 281%/459%/412% YoY growth in "peptide therapy" searches across Google/TikTok/Instagram (Glossy, April 2026) is consumer demand pull, not supply-side launch. Augur: the absence of a Hims announcement coinciding with this scale of consumer interest is itself a signal — they appear to be waiting for either PCAC cover or a smaller competitor's first-mover scar. Bayesian: prior 0.84, posterior 0.84.

A MedicalXpress report (April 2026) documents an AI methodology that scanned 400,000 Reddit posts to surface overlooked GLP-1 side effects — the technique transfers directly to compounded peptides. This is a detection-channel signal: the time between anonymous user complaint and citable adverse-event corpus is collapsing. Combined with Preventive Medicine Daily's gray-market pharmacovigilance analysis (arsenic 10× injectable toxicity limits, lead contamination) and the existing Medscape/ISMP/ECRI escalation, the discourse infrastructure is now equipped to convert anecdote into headline-grade evidence faster than the prior reference class assumed. Historian: the reference class for trend-driven supplement scandals (kratom 2018, kava 2002, ephedra 2003) shows institutional warning → academic adverse-event paper → top-5 outlet feature in a 6–12 month window. We are at month 3 of that arc. Skeptic: falsifier still requires a top-5 US outlet feature; AI Reddit-mining is upstream of that, not the falsifier itself. Counter-narrative: if Cat 1 reclassification channels demand to regulated 503A compounders, gray-market headline risk drops. Bayesian: prior 0.65, posterior 0.67. +0.02 for detection-methodology institutionalization absent a trigger event.

46 days to July 1. NCPA confirmed (May 11) that CMS updated the Bridge website. AMCP's pharmacist FAQ continues to circulate. CMS confirmed pharmacies need no opt-in and a dedicated BIN 028918 / PCN MEDDGLP1BR routes Bridge claims to a central processor — operational rails hardening. BUT: CMS also confirmed only the Zepbound KwikPen is eligible — vial and single-dose pen formulations of Zepbound are excluded, which narrows the practical Zepbound patient pool meaningfully (vials are the dominant tirzepatide format). Demand infrastructure +, drug eligibility narrowed −. Bayesian: prior 0.72, posterior 0.72.

No new peptide DTC affiliate programs. GLP-1 CPA dominance ($260 vs $8–40 structural) unchanged. Bayesian: prior 0.85, posterior 0.85. compound-peptide-property-live: holds 0.85, flagged for operator resolution. Per operator clarification 2026-05-15, the broader portfolio-ship interpretation (HRT Picks + glp1pets + Titrate + /numbers) is satisfied. Recommend operator resolve as TRUE on the broader interpretation and retire the narrow peptide-adjacent wording. Today's 7-day execution-decay check is moot under that interpretation. Flag: true.